Modeling hard clinical end-point data in economic analyses

Author： Kansal Anuraag R.   Zheng Ying   Palencia Roberto   Ruffolo Antonio   Hass Bastian   Sorensen Sonja V.  

Publisher： Informa Healthcare

ISSN： 1369-6998

Source： Journal of Medical Economics, Vol.16, Iss.11, 2013-11, pp. : 1327-1343

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Is Doubling of Serum Creatinine a Valid Clinical ‘Hard’ Endpoint in Clinical Nephrology Trials?

By  

Nephron Clin Pract, Vol. 119, Iss. 3, 2011-08 ,pp. : c195-c199

Karger

Access to resources Recommend Favorite

Assessing a composite end point for new tocolytics in clinical trials: Data from 4 US integrated delivery networks

By  

PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, Vol. 27, Iss. 2, 2018-02 ,pp. : 213-220

John Wiley & Sons Inc

Access to resources Recommend Favorite

Homeopathy: Meta-Analyses of Pooled Clinical Data

By  

Forschende Komplementärmedizin / Research in Complementary Medicine, Vol. 20, Iss. 5, 2013-10 ,pp. : 376-381

Karger

Access to resources Recommend Favorite

Exploratory Point Pattern Analysis for Modeling Biological Data

By  

International Journal of Systems Biology and Biomedical Technologies (IJSBBT), Vol. 2, Iss. 1, 2013-01 ,pp. : 1-13

IGI Global_journal

Access to resources Recommend Favorite

Clinical trials of idiopathic pulmonary fibrosis: choosing the (right) primary end point

By Spagnolo Paolo   Luppi Fabrizio  

Clinical Investigation, Vol. 3, Iss. 12, 2013-12 ,pp. : 1139-1146

Future Science

Access to resources Recommend Favorite